



***Study of cerebral circulation  
hemodynamics in prevalent hemodialysis  
patients***

*Thesis*

*Submitted for partial fulfillment of Master Degree in internal  
medicine*

Presented by

**Mahmoud Sadek AL-Semrawy**

*M.B. B.Ch.*

Supervised by

**Prof. Dr. *AbdEL-baset AL Shaarawy*  
*Abd EL-Azeem***

*Professor of Internal Medicine and Nephrology*

*Faculty of Medicine, Ain Shams University*

**Dr. *Maha Abd EL-Moneim Behairy***

*Lecturer of Internal Medicine and Nephrology*

*Faculty of Medicine, Ain Shams University*

**Dr. *Ahmed Mohammed EL-Sadek***

*Lecturer of Neurology*

*Faculty of Medicine, Ain Shams University*

**Faculty of Medicine  
Ain Shams University**

**2017**



## □ دراسة الدورة الدموية المخية في مرضي الغسيل الكلوي المزمن

رسالة

توطئة للحصول علي درجة الماجستير في امراض الباطنه العامه  
مقدمة من

□ **محمود صادق السمرائي/الطبيب**

بكالوريوس الطب و الجراحة

تحت إشراف

□ **أ.د/ عبدالباسط الشعراوي عبدالعظيم**

أستاذ امراض الباطنة والكلي

كلية الطب- جامعة عين شمس

**د/ مها عبدالمنعم بحيري**

مدرس امراض الباطنة والكلي

كلية الطب- جامعة عين شمس

□ **د/ أحمد محمد الصادق**

مدرس طب المخ والأعصاب

كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٧

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَانِكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدقة الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgement

*First of all, thanks to Allah*

*I would like to express and extend my deepest gratitude to Allah the Almighty who has bestowed me with his blessings and strengthened me throughout my research.*

*I am heartily grateful to my supervisor **Prof. Dr AbdEl-Baset Al Shaarawy Abd El-Azeem** for sharing his pearls of wisdom and expertise together with her unceasing advice and genuine attention.*

*I am also indebted to **Dr. Maha Abd El-Moneim Behairy** whose guidance and support enabled me to develop a thorough understanding to the subject of my thesis, whom without her help, this work would have never been accomplished.*

*I would like to express my deep gratitude and respect to **Dr. Ahmed Mohammed El-Sadek**, who deal with me as his young brother, for his great help, expert supervision, valuable advice and sincere support for doing this research.*

*I would like to express my deep thanks and gratitude to **Dr. Hossam El-Din Mahmoud Afifi**, Lecturer of neurology, Ain shams university for his great supportive help and educational way in the analysis and reaching the results of this work.*

*Finally, I take this opportunity to express my acknowledgment to my family for their support, and also my patients and everyone who directly or indirectly helped and inspired me.*

✍**Mahmoud Sadek Mahmoud Al Semrawy .**

## *Contents*

<b>Subjects</b>	<b>Page</b>
• <b>List of Abbreviations .....</b>	<b>I</b>
• <b>List of table .....</b>	<b>II</b>
• <b>List of Figures .....</b>	<b>III</b>
• <b>Introduction .....</b>	<b>1</b>
• <b>Aim of the Work.....</b>	<b>3</b>
• <b>Review of literature: .....</b>	<b>4</b>
Chapter 1: Cerebral circulation disorders in chronic kidney disease .....	
Chapter 2: Methods of assessment of cerebral circulation	
• <b>Patients And Methods.....</b>	<b>36</b>
• <b>Results.....</b>	<b>41</b>
• <b>Discussion .....</b>	<b>58</b>
• <b>Summary .....</b>	<b>65</b>
• <b>Conclusion .....</b>	<b>68</b>
• <b>Recommendations .....</b>	<b>69</b>
• <b>References .....</b>	<b>70</b>
• <b>Arabic Summary .....</b>	<b>-</b>

---

## *List of Abbreviations*

<b>ACA</b>	:	Anterior cerebral artery
<b>ACZ</b>	:	Acetazolamide
<b>ADMA</b>	:	Asymmetric dimethyl arginine.
<b>ALT</b>	:	Alanine transaminase
<b>AST</b>	:	Aspartate transaminase
<b>BA</b>	:	Basilar artery
<b>BP</b>	:	Blood pressure
<b>BUN</b>	:	Blood urea nitrogen
<b>BOLD</b>	:	Blood oxygen level dependent
<b>CA</b>	:	Cerebral autoregulation
<b>CAD</b>	:	Coronary artery disease
<b>CBF</b>	:	Cerebral blood flow
<b>CBS</b>	:	Cystathionine B synthase
<b>CBV</b>	:	Cerebral blood volume
<b>CI</b>	:	Cognitive impairment
<b>CKD</b>	:	Chronic kidney disease
<b>CPP</b>	:	Cerebral perfusion pressure
<b>CRP</b>	:	C-reactive protein
<b>CT</b>	:	Computed tomography
<b>CVD</b>	:	Cardiovascular disease
<b>CVR</b>	:	Cerebral vasomotor reactivity
<b>eGFR</b>	:	Estimated glomerular filtration rate
<b>ESRD</b>	:	End stage renal disease
<b>FBS</b>	:	Fasting blood sugar
<b>FMRI</b>	:	Functional magnetic resonance imaging
<b>FV</b>	:	Flow velocity
<b>GM</b>	:	Gray matter
<b>Hb</b>	:	Hemoglobin
<b>HCY</b>	:	Homocysteine
<b>HD</b>	:	Hemodialysis
<b>HDL</b>	:	High density lipoprotein
<b>HGF</b>	:	Hepatocyte growth factor
<b>ICA</b>	:	Internal carotid artery
<b>ICH</b>	:	Intra cerebral hemorrhage
<b>ICP</b>	:	Intra cranial pressure
<b>in</b>	:	Inch
<b>INR</b>	:	International normalized ratio
<b>iPTH</b>	:	Intact parathyroid hormone

---

---

## *List of Abbreviations*

---

<b>K</b>	:	Potassium
<b>kg/m<sup>2</sup></b>	:	Kilogram/meter square
<b>LDL</b>	:	Low density lipoprotein
<b>LP</b>	:	Lipoprotein
<b>LVD</b>	:	Left ventricular dysfunction
<b>LVH</b>	:	Left ventricular hypertrophy
<b>MAP</b>	:	Mean arterial pressure
<b>MCA</b>	:	Middle cerebral artery
<b>MFV</b>	:	Mean flow velocity
<b>Mg</b>	:	Magnesium
<b>MRI</b>	:	Magnetic resonance imaging
<b>Na</b>	:	Sodium
<b>NIRS</b>	:	Near infrared spectroscopy
<b>NO</b>	:	Nitric oxide
<b>OA</b>	:	Ophthalmic artery
<b>OEF</b>	:	Oxygen extraction fraction
<b>PCA</b>	:	Posterior cerebral artery
<b>PET</b>	:	Positron emission tomography
<b>pg</b>	:	Picogram/milliliter
<b>PI</b>	:	Pulsatility index
<b>Po<sub>4</sub></b>	:	Phosphate
<b>PTH</b>	:	Parathyroid hormone
<b>SAH</b>	:	Subarachnoid hemorrhage
<b>SCI</b>	:	Silent cerebral infarction
<b>SD</b>	:	Standard deviation
<b>SPECT</b>	:	Single photo emission computed tomography
<b>TCCD</b>	:	Transcranial color coded duplex
<b>TCD</b>	:	Transcranial Doppler
<b>TIA</b>	:	Transient ischemic attack
<b>TICA</b>	:	Terminal portion of the internal carotid artery
<b>URR</b>	:	Urea reduction ratio
<b>VR</b>	:	Vertebral artery
<b>WMH</b>	:	White matter hyperintensities

## *List of Tables*

<i>Tab. No.</i>	<i>Subject</i>	<i>Page</i>
<b>Table (1)</b>	Demographic and Clinical data of the study population.	٤٢
<b>Table (2)</b>	Medications taken by patients.	٤٢
<b>Table (3)</b>	Laboratory data of the studied patients.	٤٣
<b>Table (4)</b>	Average of mean flow velocities in MCA and PCA.	٤٣
<b>Table (5)</b>	Descriptive parameters of trans cranial Doppler.	٤٤
<b>Table (6)</b>	Comparison between MCA decreased versus MCA normal group.	٤٥
<b>Table (7)</b>	Comparison between MCA decreased versus MCA normal group.	٤٦
<b>Table (8)</b>	Comparison between PCA decreased versus PCA normal group.	٤٧
<b>Table (9)</b>	Comparison between PCA decreased versus PCA normal group.	٤٨
<b>Table (10)</b>	Comparison between HCV positive and negative regarding mfvs of MCA and PCA.	٤٩
<b>Table (11)</b>	Correlation between MCA score and epidemiological and lab parameters.	٥٠
<b>Table (12)</b>	Correlation between MCA score and gender and URR.	٥١
<b>Table (13)</b>	Correlation between PCA score and all-studied parameters.	٥٣
<b>Table (14)</b>	Correlation between PCA score and URR and gender.	٥٤
<b>Table (15)</b>	Multivariate regression analysis of MCA as dependent variable.	٥٦
<b>Table (16)</b>	Multivariate regression analysis of PCA as dependent variabl.	٥٧



## *List of Figures of review of literature*

<b>Fig. No.</b>	<b>Subject</b>	<b>Page</b>
<b>Fig. (1)</b>	Intact cerebral autoregulation.	6
<b>Fig. (2)</b>	Impaired cerebral autoregulation.	6
<b>Fig. (3)</b>	Potential causes of cognitive impairment in patient with CKD .	21
<b>Fig. (4)</b>	How cardiovascular risk factors give rise to disturbed hemodynamic flow patterns inducing cerebral hypoperfusion.	24
<b>Fig. (5)</b>	Position of TCD probe insonated through temporal foramen.	27
<b>Fig. (6)</b>	TCD probe positions over different acoustic windows of the skull.	30
<b>Fig. (7)</b>	TCD screen waveform.	31

## *List of Figures of results*

<b>Fig. No.</b>	<b>Subject</b>	<b>Page</b>
<b>Fig. (1)</b>	Frequency of patients with decreased MFVs of MCA.	46
<b>Fig. (2)</b>	Frequency of patients with decreased MFVs of MCA.	48
<b>Fig. (3)</b>	Comparison between HCV positive and negative regarding the average of MFVs in MCA and PCA.	49
<b>Fig. (4)</b>	Correlation between MCA score and URR value.	51
<b>Fig. (5)</b>	Correlation between MCA score and URR value.	52
<b>Fig. (6)</b>	Correlation between PCA score and hemoglobin level.	54
<b>Fig. (7)</b>	Correlation between PCA score and gender.	55

## Abstract

In the current study, fifty prevalent HD patients were included from El Sahel teaching hospital dialysis units. All patients were on regular HD thrice weekly for at least 6 month, each dialysis session lasted four hours with clinically stable condition. In our study we exclude patients with cerebrovascular insult, active collagen disease, diabetes mellitus, uncontrolled hypertension, severe anemia  $\leq 8$  g/dl, decompensated chronic liver disease , heavy smokers and active inflammation. All patients were subjected to clinical examination; Fasting serum samples were obtained. All biochemical blood samples were collected before the mid-week HD session and before heparin administration. Laboratory investigations included: Hemoglobin level, urea (pre& post dialysis), creatinine, Urea reduction ratio (URR), albumin, calcium, phosphorus, PTH, CRP titer, lipid profile, and HCV Ab were done. An informed detailed consent was taken from the patients before the start of the study.

Cerebral circulation was assessed by measuring mean flow velocity in middle cerebral artery and posterior cerebral artery in non-dialysis day using trans cranial Doppler sonography machine.

This study included 18 (32%) female patients and 27 (68%) male patients with mean of age 43.4 years and range from 22-62 years. The mean of HD duration was 71.36 months.

**Key word:**

Blood oxygen level dependent, C-reactive protein, Fasting blood sugar, Intra cerebral hemorrhage, Magnesium , Parathyroid hormone.

## **Introduction**

Hemodialysis is the most common treatment for ESRD. Transient hypotension, arterial hypoxemia ,and fluctuations in electrolytes and cerebral water content might occur during hemodialysis and possibly induce subtle brain damage. It is unestablished whether dialysis treatment improves or exacerbates the cognitive deficits of ESRD or the underlying cardiovascular disease (*Monk and Bennett, 2006*). Previous literature suggests the possibility of deleterious hemodialysis effects on cognition (*Gilli and De Bastiani, 1983*).

Patients with End-stage renal disease (ESRD) are at increased risk of cerebrovascular diseases with a risk approximately 5-10 times higher than the general population. Signs of cerebrovascular disease are common and suggestive of vascular related injury (*Sozio et al,2009*).

ESRD has been associated with accelerated vascular disease and premature atherosclerosis of the cerebral circulation due to uremic toxins and augmentation of traditional risk factors of atherosclerosis (*Mehdi et al, 2012*).

The risk of stroke as a frequent complication of uremia, which can result from acute cerebral blood flow reduction, is five times higher in dialysis patients than the general population. Decreasing of brain tissue perfusion has deleterious nature in uremic patients, as it increases the incidence of cerebral atrophy, especially in combination with a low hematocrit and the presence of accelerated and premature atherosclerosis along with traditional risk factors (*Seligeret al,2003*).

The process of conventional hemodialysis may induce recurrent episodes of acute cerebral ischemia, which in turn may contribute to acute decline in cognitive functions during dialysis. Thus the worst time to communicate with dialysis patients may be during the hemodialysis sessions (*Murray et al, 2006*).

In the normal brain, the constancy of cerebral blood flow and volume relies on the intrinsic ability of the cerebral arteries to alter their caliber in response to variations in blood pressure (auto regulation). Changes in regional metabolic demands with ESRD patients, cerebral vessels undergo structural changes, with subsequent impairment in the hemodynamic auto regulation processes, making stroke frequent complication in uremic patients on dialysis(*KuwabaraY et al,2002*).

## **Aim of the work**

To evaluate cerebral circulation hemodynamics in prevalent hemodialysis patients by trans cranial Doppler sonography.

## **Cerebral circulation disorders in chronic kidney disease**

Normal Cerebral Blood Flow (CBF):

The human brain represents approximately 2% of total body weight, yet it receives approximately 20% of cardiac output and uses 20% of total body oxygen consumed under normal conditions. In this situation, most of the energy of the brain is obtained exclusively from aerobic metabolic process. The impairment in the supply of nutrients and oxygen to the brain can cause cellular damage (*Bor-seng et al, 2012*).

Regulation of cerebral blood flow:

Regulation of blood flow in the human brain is exceedingly complex. There are three main regulatory parameters involved in the regulation of cerebral blood flow: cerebral auto regulation, flow-metabolism coupling, and neurogenic regulation. In addition, there are two cell types that have repeatedly been shown to play a central role in the regulation of cerebral blood flow: endothelial cells and astrocytes (*Peterson et al, 2011*).

1. Cerebral auto regulation:

Cerebral Auto regulation (CA) is the intrinsic ability of the brain to maintain stable cerebral blood flow (CBF) while mean arterial blood pressure (MAP) and cerebral

perfusion pressure (CPP) are changing. It constitutes a regulatory mechanism to provide metabolic substrates under physiological and pathological conditions. Constant CBF is regulated by changing arteriolar diameter, which will alter cerebral blood volume (CBV) and ultimately, intra-cranial pressure (ICP) (*Bor-seng et al, 2012*).

**Cerebral Auto regulation (CA) has two components;**

- (a) **Metabolic Auto regulation;** which is the cerebrovascular response to changes in brain tissue PH. Vasodilatation occurs when tissue PH drops during ischemia, hypoxia or hypercapnic events, in contrast respiratory alkalosis results in cerebral vasoconstriction. Metabolic auto regulation can be measured via the CBF response to change in  $\text{paCO}_2$  (*Lang et al, 2005*).
- (b) **Pressure Auto regulation,** which is the cerebrovascular response to changes in trans mural vascular pressure resulting from changes in CPP or MAP. Moreover, Pressure auto regulation has a slow component, referred to as “static CA” and a fast component, namely “dynamic CA”. In normal situation, where pressure auto regulation is intact, CBF is kept constant over the range of arterial pressure from 50-150mmHg. Below and above the ABP range, pressure auto regulation is no longer maintained and CBF approximates to a linear relationship with CPP (Figure 1, 2) (*Lang et al, 2005*).